# Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

> **NCT01456585** · PHASE1 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 10 (estimated)

## Conditions studied

- Adenocarcinoma Pancreas

## Interventions

- **OTHER:** Gemcitabine
- **DRUG:** CP-870,893

## Key facts

- **NCT ID:** NCT01456585
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01456585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01456585, "Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01456585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*